172 related articles for article (PubMed ID: 20550538)
1. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.
Tan T; Cabrita IZ; Hensman D; Grogono J; Dhillo WS; Baynes KC; Eliahoo J; Meeran K; Robinson S; Nihoyannopoulos P; Martin NM
Clin Endocrinol (Oxf); 2010 Sep; 73(3):369-74. PubMed ID: 20550538
[TBL] [Abstract][Full Text] [Related]
2. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study.
Nachtigall LB; Valassi E; Lo J; McCarty D; Passeri J; Biller BM; Miller KK; Utz A; Grinspoon S; Lawson EA; Klibanski A
Clin Endocrinol (Oxf); 2010 Jan; 72(1):53-8. PubMed ID: 19508591
[TBL] [Abstract][Full Text] [Related]
3. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly.
Maione L; Garcia C; Bouchachi A; Kallel N; Maison P; Salenave S; Young J; Assayag P; Chanson P
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1714-9. PubMed ID: 22723314
[TBL] [Abstract][Full Text] [Related]
4. [Cabergoline in hyperprolactinemia and valvular heart disease].
Vargas ML; Cervantes CE; Hernando CA; Da Costa CV
Endocrinol Nutr; 2009 Oct; 56(8):412-7. PubMed ID: 19959151
[TBL] [Abstract][Full Text] [Related]
5. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.
Wakil A; Rigby AS; Clark AL; Kallvikbacka-Bennett A; Atkin SL
Eur J Endocrinol; 2008 Oct; 159(4):R11-4. PubMed ID: 18625690
[TBL] [Abstract][Full Text] [Related]
6. [Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].
Steffensen C; Mægbæk ML; Laurberg P; Andersen M; Kistorp C; Nørrelund H; Dal J; Jørgensen JO
Ugeskr Laeger; 2014 Jan; 176(1):58-60. PubMed ID: 24629610
[TBL] [Abstract][Full Text] [Related]
7. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.
Auriemma RS; Pivonello R; Perone Y; Grasso LF; Ferreri L; Simeoli C; Iacuaniello D; Gasperi M; Colao A
Eur J Endocrinol; 2013 Sep; 169(3):359-66. PubMed ID: 23824978
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline and the risk of valvular lesions in endocrine disease.
Lancellotti P; Livadariu E; Markov M; Daly AF; Burlacu MC; Betea D; Pierard L; Beckers A
Eur J Endocrinol; 2008 Jul; 159(1):1-5. PubMed ID: 18456868
[TBL] [Abstract][Full Text] [Related]
9. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.
Bogazzi F; Buralli S; Manetti L; Raffaelli V; Cigni T; Lombardi M; Boresi F; Taddei S; Salvetti A; Martino E
Int J Clin Pract; 2008 Dec; 62(12):1864-9. PubMed ID: 18462372
[TBL] [Abstract][Full Text] [Related]
10. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
Lafeber M; Stades AM; Valk GD; Cramer MJ; Teding van Berkhout F; Zelissen PM
Eur J Endocrinol; 2010 Apr; 162(4):667-75. PubMed ID: 20071478
[TBL] [Abstract][Full Text] [Related]
11. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma.
Halperin I; Aller J; Varela C; Mora M; Abad A; Doltra A; Santos AE; Batista E; García-Pavía P; Sitges M; Mirelis JG; Lucas T; Puig-Domingo M
Clin Endocrinol (Oxf); 2012 Aug; 77(2):275-80. PubMed ID: 22288503
[TBL] [Abstract][Full Text] [Related]
12. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
[TBL] [Abstract][Full Text] [Related]
13. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.
Herring N; Szmigielski C; Becher H; Karavitaki N; Wass JA
Clin Endocrinol (Oxf); 2009 Jan; 70(1):104-8. PubMed ID: 19128367
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia.
Devin JK; Lakhani VT; Byrd BF; Blevins LS
Endocr Pract; 2008 Sep; 14(6):672-7. PubMed ID: 18996784
[TBL] [Abstract][Full Text] [Related]
15. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
[TBL] [Abstract][Full Text] [Related]
16. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
[TBL] [Abstract][Full Text] [Related]
17. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.
Colao A; Galderisi M; Di Sarno A; Pardo M; Gaccione M; D'Andrea M; Guerra E; Pivonello R; Lerro G; Lombardi G
J Clin Endocrinol Metab; 2008 Oct; 93(10):3777-84. PubMed ID: 18682513
[TBL] [Abstract][Full Text] [Related]
18. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study.
Delgado V; Biermasz NR; van Thiel SW; Ewe SH; Marsan NA; Holman ER; Feelders RA; Smit JW; Bax JJ; Pereira AM
Clin Endocrinol (Oxf); 2012 Jul; 77(1):99-105. PubMed ID: 22211510
[TBL] [Abstract][Full Text] [Related]
19. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy.
Italiano D; Bianchini E; Ilardi M; Cilia R; Pezzoli G; Zanettini R; Vacca L; Stocchi F; Bramanti P; Ciurleo R; Di Lorenzo G; Polimeni G; de Luise C; Ross D; Rijnbeek P; Sturkenboom M; Trifirò G
J Neural Transm (Vienna); 2015 Jun; 122(6):799-808. PubMed ID: 25230720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]